MEDICLIN AG (MED.DE) Stock Fundamental Analysis
FRA:MED - DE0006595101 - Common Stock
3.1 EUR
+0.1 (+3.33%)
MED gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 28 industry peers in the Health Care Providers & Services industry. MED has an excellent profitability rating, but there are some minor concerns on its financial health. MED is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year MED was profitable.
MED had a positive operating cash flow in the past year.
In multiple years MED reported negative net income over the last 5 years.
MED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MED has a Return On Assets of 3.76%. This is in the better half of the industry: MED outperforms 67.86% of its industry peers.
MED has a better Return On Equity (14.64%) than 71.43% of its industry peers.
With a decent Return On Invested Capital value of 6.72%, MED is doing good in the industry, outperforming 71.43% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for MED is below the industry average of 6.48%.
The 3 year average ROIC (3.46%) for MED is below the current ROIC(6.72%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.76% | ||
| ROE | 14.64% | ||
| ROIC | 6.72% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
MED's Profit Margin of 4.34% is fine compared to the rest of the industry. MED outperforms 64.29% of its industry peers.
In the last couple of years the Profit Margin of MED has grown nicely.
The Operating Margin of MED (8.17%) is better than 71.43% of its industry peers.
MED's Operating Margin has improved in the last couple of years.
The Gross Margin of MED (83.90%) is better than 78.57% of its industry peers.
In the last couple of years the Gross Margin of MED has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.17% | ||
| PM (TTM) | 4.34% | ||
| GM | 83.9% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
MED has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, MED has about the same amount of shares outstanding.
Compared to 5 years ago, MED has about the same amount of shares outstanding.
MED has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.50, we must say that MED is in the distress zone and has some risk of bankruptcy.
MED has a Altman-Z score (1.50) which is comparable to the rest of the industry.
The Debt to FCF ratio of MED is 10.50, which is on the high side as it means it would take MED, 10.50 years of fcf income to pay off all of its debts.
With a Debt to FCF ratio value of 10.50, MED perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
MED has a Debt/Equity ratio of 1.84. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of MED (1.84) is worse than 67.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.84 | ||
| Debt/FCF | 10.5 | ||
| Altman-Z | 1.5 |
ROIC/WACC1.47
WACC4.58%
2.3 Liquidity
A Current Ratio of 1.82 indicates that MED should not have too much problems paying its short term obligations.
MED's Current ratio of 1.82 is amongst the best of the industry. MED outperforms 82.14% of its industry peers.
A Quick Ratio of 1.78 indicates that MED should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.78, MED belongs to the top of the industry, outperforming 89.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.78 |
3. Growth
3.1 Past
MED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 327.10%, which is quite impressive.
MED shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.79% yearly.
MED shows a small growth in Revenue. In the last year, the Revenue has grown by 1.64%.
Measured over the past years, MED shows a small growth in Revenue. The Revenue has been growing by 2.19% on average per year.
EPS 1Y (TTM)327.1%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%395.24%
Revenue 1Y (TTM)1.64%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%8.62%
3.2 Future
The Earnings Per Share is expected to grow by 13.85% on average over the next years. This is quite good.
Based on estimates for the next years, MED will show a small growth in Revenue. The Revenue will grow by 2.80% on average per year.
EPS Next Y52.44%
EPS Next 2Y14.23%
EPS Next 3Y13.85%
EPS Next 5YN/A
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 4.37, the valuation of MED can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of MED indicates a rather cheap valuation: MED is cheaper than 100.00% of the companies listed in the same industry.
MED's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.13.
With a Price/Forward Earnings ratio of 5.74, the valuation of MED can be described as very cheap.
MED's Price/Forward Earnings ratio is rather cheap when compared to the industry. MED is cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.76. MED is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.37 | ||
| Fwd PE | 5.74 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MED indicates a rather cheap valuation: MED is cheaper than 92.86% of the companies listed in the same industry.
MED's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MED is cheaper than 85.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.39 | ||
| EV/EBITDA | 2.99 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MED may justify a higher PE ratio.
MED's earnings are expected to grow with 13.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.08
PEG (5Y)0.21
EPS Next 2Y14.23%
EPS Next 3Y13.85%
5. Dividend
5.1 Amount
MED has a Yearly Dividend Yield of 1.29%.
MED's Dividend Yield is a higher than the industry average which is at 2.70.
Compared to an average S&P500 Dividend Yield of 2.32, MED's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.29% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y14.23%
EPS Next 3Y13.85%
FRA:MED (8/28/2025, 7:00:00 PM)
3.1
+0.1 (+3.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners1.7%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap147.25M
Analysts83.33
Price Target4.79 (54.52%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.29% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)26.26%
EPS NY rev (3m)26.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.37 | ||
| Fwd PE | 5.74 | ||
| P/S | 0.19 | ||
| P/FCF | 3.39 | ||
| P/OCF | 1.58 | ||
| P/B | 0.64 | ||
| P/tB | 0.71 | ||
| EV/EBITDA | 2.99 |
EPS(TTM)0.71
EY22.9%
EPS(NY)0.54
Fwd EY17.43%
FCF(TTM)0.91
FCFY29.46%
OCF(TTM)1.96
OCFY63.29%
SpS16.46
BVpS4.88
TBVpS4.37
PEG (NY)0.08
PEG (5Y)0.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.76% | ||
| ROE | 14.64% | ||
| ROCE | 8.66% | ||
| ROIC | 6.72% | ||
| ROICexc | 8.86% | ||
| ROICexgc | 9.27% | ||
| OM | 8.17% | ||
| PM (TTM) | 4.34% | ||
| GM | 83.9% | ||
| FCFM | 5.55% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexcg growth 3Y64.29%
ROICexcg growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.84 | ||
| Debt/FCF | 10.5 | ||
| Debt/EBITDA | 3.69 | ||
| Cap/Depr | 96.31% | ||
| Cap/Sales | 6.37% | ||
| Interest Coverage | 2.92 | ||
| Cash Conversion | 80.6% | ||
| Profit Quality | 127.75% | ||
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.78 | ||
| Altman-Z | 1.5 |
F-Score8
WACC4.58%
ROIC/WACC1.47
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)327.1%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%395.24%
EPS Next Y52.44%
EPS Next 2Y14.23%
EPS Next 3Y13.85%
EPS Next 5YN/A
Revenue 1Y (TTM)1.64%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%8.62%
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
EBIT growth 1Y377.48%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year131.21%
EBIT Next 3Y31.07%
EBIT Next 5YN/A
FCF growth 1Y195.08%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.79%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%